Description

What is Lucipona 45mg? 

Lucipona 45Mg is the Ponatinib formulation medicine, which is a strong oral inhibitor for tyrosine kinase. It is used in the management of chronic myeloid leukemia (CML) and is also prescribed for the management of certain types of blood cancers. Ponatinib 45Mg is also prescribed for Philadelphia chromosome-positive acute lymphoblastic leukemia, as granted by the FDA. It is manufactured by Lucius Pharmaceuticals.  

What is the Use of Lucipona 45mg? 

It is a powerful kinase inhibitor used for treating adult patients suffering from chronic myeloid leukemia (CML) and Chronic phase (CP). The active ingredient is Ponatinib and is prescribed for patients with CML and CP. It is also used in combination with therapies indicated for blood cancers.  

Lucipona 45 Mg can be used in patients who are:  

• Adults with accelerated and chronic, blast phase chronic myeloid leukemia (CML), who had not shown promising results from the TKI treatment previously.  

• Adults struggling with Philadelphia chromosome-positive Acute Lymphoblastic Leukemia. They may be the ones who have shown resistance and intolerance to TKI therapies in the past.  

• In need of therapies for T315I-positive CML and Ph+ ALL.  

• Lucipona 45mg should not be treated as the first-line treatment. However, it is a trusted treatment option for individuals who could not show a positive response to other treatments.  

Benefits of Lucipona 45mg 

• Lucipona 45 mg is effective against the T315I mutation and other forms of resistant mutations, which cannot be treated with TKIs of the first and second generation.  

• Kinase inhibition of a broader spectrum can be useful against proteins that drive cancer.  

• Patients who may not have responded suitably to standard treatments still have some hope. 

• Better than intravenous drugs, as it is an oral medication.  

• Relapsed or advanced leukemias may see more survival outcomes.  

How Does Lucipona 45mg Work? 

Lucipona 45 mg works as it binds to the ATP of  BCR-ABL medication which is a tyrosine kinase. BCR-ABL is the fusion protein that is regularly active and promotes improper growth in CML. Ponatinib blocks the activity of the protein. It also includes T315I mutation after it renders TKIs ineffective.  

Not just BCR-ABL, lucipona 45mg can also lead to inhibition of kinases that include FGFR, VEGFR, KIT, PDGFR, RET, as well as FLT3. It also helps with anti-cancer activities as Ponatinib Tablet is an anti-cancer agent.  

How to take Lucipona 45mg Tablet? 

The recommended initial dose for Lucipona is supposed to be 45mg (to be taken once daily). It can be taken orally without or with a meal. Ponatinib Tablet must be consumed wholly and is not to be taken after chewing, breaking, or crushing. Lucipona Dosage can be based on the patient’s responsiveness towards its use.  

Following instructions can help:  

• Patients must take regular blood tests for the management of therapeutic development so that the negative influences can be detected in advance.  

• Lucipona 45 Mg tablet must be consumed at just the same time on each day. 

• Dosage must not be doubled if it is after a missed dose.  

• Stay hydrated and drink sufficient water if the doctor has not suggested otherwise.  

Lucipona Dosage 

Recommended dosage for Lucipona 45mg in:  

CP-CML: 45mg is the starting dose, to be reduced to 15mg per day after ≤1% BCR-ABL1 levels are achieved.  

AP-CML, Ph+ALL, and BP-CML: Starting dose is 45mg oral to be taken once each day.  

Hepatic Impairment: Starting dose should be reduced to 30mg orally once a day.  

The lucipona 45 mg must be used either with food or without one.   

Available in various formulations like 15mg, 30mg, and 45mg, dosage modifications are important in patients with:  

• Adverse events that may include pancreatitis, hypertension, and liver toxicity. In such patients, the dose may be reduced to 15 or 30mg.  

• Certain drug interactions that may occur when the Lucipona 45 mg is taken with CYP3A inhibitors, which indicates the need for dose adjustment.  

• Hepatic/Renal impairment in which close monitoring is needed rather than specific dose changes. 

Lucipona Side-effect 

Common side effects of Ponatinib Tablet may include: 

• Rash 

• Itching 

• Dry skin 

• Weakness 

• Fatigue  

• Vomiting 

• Diarrhea  

• Nausea 

• Headache  

• Abdominal pain 

• Infections or fever 

Severe side effects of Ponatinib Tablet may include:  

• Arterial occlusive events (peripheral cardiac ailments, stroke, heart attack, etc.) 

• Venous Thromboembolism that may also involve pulmonary embolism as well as the deeper vein thrombosis.  

• Liver toxicity 

• Hypertension 

• Pancreatitis 

• Low blood counts/ Myelosuppression 

• Cardiac failure  

Patients must regularly monitor blood pressure, liver enzyme levels, blood counts, and cardiac function.  

Precautions of Lucipona 45mg 

• Lucipona 45 mg contains Ponatinib 45Mg which may cause heart failure and fluid retention. 

• It should not be utilized with other Ponatinib tablets.  

• Patients must inform their doctor about any past alcohol use, blood clotting, hypertension, heart rhythm, liver disease, Neutropenia, Thrombocytopenia, bowel problems, Pancreatitis, or related problems.  

• Patients with problems of diabetes, cardiac attack history, blood vessel disease, stroke, or Hyperlipidemia should report to the healthcare professional.  

Storage  

Storage should be within 20°C and 25°C. Direct sunshine, dampness, and heat should be avoided. The product should not come in contact with pets and children.  

Where to Buy Lucipona 45mg Online? 

Lucipona 45 mg can be ordered on trusted online pharmacies that sell authentic and quality medications sourced from trusted manufacturers and suppliers only. This is crucial for the health status of an individual. You may buy from Medzsupplier, which sells genuine and FDA-approved Chronic myeloid leukemia medications at lower prices. Keep an eye on discounts and offers available from time to time, making bulk purchases a pocket-friendly venture.